Second-line treatment for advanced colorectal cancer
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital clinical trials.
This trial tests a combination of drugs for people with advanced colorectal cancer that has worsened after first treatment. It aims to see if this new mix can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced colorectal cancer that has spread (metastatic).
- Your cancer has a specific marker called pMMR/MSS.
- You stopped your first treatment due to side effects or the cancer got worse.
- You are able to do daily activities with some help (ECOG 0-2).
- You have not had prior treatment with irinotecan or immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new combination drug, LBL-024, for people with colorectal cancer that has spread to other parts of the body. The goal is to see if the combination can shrink tumors or slow down the cancer's growth.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial compares two different drug combinations for people with advanced colorectal cancer that has grown after first treatment. It tests whether a newer drug (fruquintinib) combined with standard chemotherapy works as well as the current standard (bevacizumab) combined with chemotherapy.
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.